TITLE

Cells Show Promise for Parkinson's

PUB. DATE
July 2008
SOURCE
Technology Review;Jul2008, Vol. 111 Issue 4, p92
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents a study that assesses the capabilities of brain cells developed from skin cells to alleviate the symptoms and pain in Parkinson's disease. Rudolf Jaenish and colleagues administered the study by transforming mouse skin cells into undifferential cells induced into four different genetic types and integrate in the brain as well as transplanted reprogrammed cells that suppress the release of chemical toxins. The study reveals that reprogrammed cells are capable to function as stem cells which help reduces the symptoms of Parkinson's disease. In addition, the author notes that the research manifest its potentials in treating such diseases wherein embryonic cells are easy to work with.
ACCESSION #
33132383

 

Related Articles

  • Stem cell therapy takes a giant leap.  // New Scientist;8/23/2008, Vol. 199 Issue 2670, p5 

    The author reflects on the use of embryonic stem cells (ESCs) to repair damaged spinal cords, hearts, livers, bones and pancreas.

  • Long-term clinical outcomes after fetal cell transplantation in parkinson disease: implications for the future of cell therapy. Bega, Danny; Krainc, Dimitri // JAMA: Journal of the American Medical Association;2/12/2014, Vol. 311 Issue 6, p617 

    IMPORTANCE: Recent advances in stem cell technologies have rekindled an interest in the use of cell replacement strategies for patients with Parkinson disease. This study reports the very long-term clinical outcomes of fetal cell transplantation in 2 patients with Parkinson disease. Such...

  • Intellectual muscle.  // New Scientist;09/23/2000, Vol. 167 Issue 2257, p7 

    Reports that stem cells from the brain can transform into muscle. Use of stem cells in muscle-wasting diseases such as muscular dystrophy; Description of an experiment by Angelo Vescovi using adult stem cells of mice and human stem cells from miscarried fetuses; Why stem cells must touch the...

  • HEAD CASE. Binns, Corey // Popular Science;Aug2007, Vol. 271 Issue 2, p16 

    This article reports on the medical treatment of a Swedish boy for infantile neuronal ceroid lipofuscinosis (NCL) which is a rare and deadly enzyme deficiency that disrupts brain function. The child received massive doses of fetal stem cells injected into his brain in China where laws are more...

  • Research Highlights.  // Molecular Therapy;Jul2011, Vol. 19 Issue 7, p1185 

    The article offers information on several studies related to gene and cell therapy. One study showed the first reported successful phase III clinical trial of a lymphoma vaccine. Another study reported having directed embryonic and induced human stem cells to become astrocytes in the laboratory...

  • Direct Reprogramming. Marbán, Eduardo; Cingolani, Eugenio // JAMA: Journal of the American Medical Association;7/7/2015, Vol. 314 Issue 1, p19 

    The authors comment on the direct reprogramming of stem cells for therapeutics. Topics covered include concerns that have restricted in vivo applications of tissues and organs to be recreated from embryonic stem cells, the limitations of induced stem cells as well as the complexity of...

  • ACT Carries the Torch for hESC Therapies Post-Geron Exit. Moran, Nuala // BioWorld Today;11/23/2011, Vol. 22 Issue 228, p2 

    The article reports on the announcement by Advanced Cell Technology (ACT) Inc. that it is about to publish results from its Phase I/II trials of retinal pigmented epithelial (RPE) cells and human embryonic stem cell (hESC)-based therapies following the abrupt withdrawal of Geron Inc. from the...

  • Stem Cell Study Patients May Need Long-Term Monitoring. Young, Donna // BioWorld Today;4/11/2008, Vol. 19 Issue 71, p1 

    The article focuses on the need for patients involved in studies of cellular therapies derived from human embryonic stem cells (hESCs) to be monitored throughout their lifetime for tumors or other abnormalities, according to the U.S. Food and Drug Administration's Cellular, Tissue and Gene...

  • Good news and bad news about Parkinson’s disease. Strupp, Michael // Journal of Neurology;Sep2008, Vol. 255 Issue 9, p1441 

    The article presents abstracts of studies on Parkinsonism, including "Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD," by R. Katzenschlager and colleagues in a 2008 issue, "Parthenogenetic dopamine neurons from primate embryonic stem cells...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics